We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

Fund managers haven’t disclosed any holdings of BIS yet.

BIS Hedge Fund Activity: Q1 2026 in Review

4 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2026, worth a combined $606K — up 114% from $283K a quarter earlier.

Fund positioning in BIS was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $333K.

  • 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $606K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2026, up 114% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2026 and 0 closed out.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2026 was Susquehanna International Group, an estimated $333K added.

Based on aggregated 13F filings for Q1 2026.